Storage Conditions: It should be sealed and stored at a temperature not exceeding 30°C, and kept out of reach of children.
Drug Type and Mechanism of Action
Venetoclax is an oral, highly selective inhibitor of the B-cell lymphoma-2 (BCL-2) protein.
By targeting and inhibiting the BCL-2 protein, which is overexpressed in various cancers, Venetoclax induces apoptosis, or programmed cell death, in cancer cells, thereby achieving therapeutic effects.
Indications
Venetoclax is the first drug worldwide approved for the treatment of chronic lymphocytic leukemia (CLL) and is also used for the treatment of small lymphocytic lymphoma (SLL).
It has also been approved for use in combination with azacitidine for the treatment of newly diagnosed adult patients with acute myeloid leukemia (AML) who are unsuitable for intensive induction chemotherapy due to comorbidities or are aged 75 years or older.
Additionally, Venetoclax is being investigated in clinical trials for the treatment of multiple myeloma (MM), lymphomas, and other hematological malignancies.
